TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* All adult patients (\>18 years of age)~* Patients undergoing standard or reverse total shoulder arthroplasty for the primary diagnoses of glenohumeral arthritis or cuff tear arthropathy~* Cognitively intact with the ability to give informed consent as outlined by our institutional review board.~* Patients must be capable of participating in the post-operative electronic survey and / or able to maintain a written diary of events~Exclusion Criteria~* Non-elective cases~* Infection, tumor, trauma~* Weight \< 50 kg~* Patients with any contraindications to regional anesthesia including allergy or hypersensitivity to amide-type local anesthetics~* Patients with allergy to any component of medication regimen e.g. amide- type local anesthetics, oxycodone, hydromorphone, fentanyl~* Chronic pain patients with history of chronic opioid use (defined as 20 mg morphine equivalent / day for greater than 30 days pre-operatively~* Concurrent painful physical condition that may require analgesic treatment that is not related to the shoulder surgery (chronic peripheral neuropathy, radiculopathy, or other neurologic disorder)~* Severe hepatic disease defined by clinical evidence of liver disease with abnormal liver function tests.~* Pregnancy~* Respiratory disease that contraindicates interscalene nerve block (elevated contralateral hemidiaphragm, contralateral pneumonectomy, or severe COPD with FEV1 \< 50% predicted, and 02 dependence)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liposomal Bupivacaine (Type: EXPERIMENTAL): Administered utilizing ultrasound guidance by an anesthesiologist. Study patients will receive 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
- Plain Bupivacaine (Type: ACTIVE_COMPARATOR): Peripheral nerve blocks will be performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride will be utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block will be utilized. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pulmonary Hypertension~* Using subcutaneous treprostinil~* Already participating as a subject in our prospective study of infusion site pain~* Has documented debilitating pain (6/10 or greater) in the study after a site change~Exclusion Criteria:~* Uncontrolled hypertension~* Recent stroke or myocardial infarction

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Qutenza patch (Type: EXPERIMENTAL): All participants actively treated with Qutenza

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 75 years of age~* On a statin or a low dose statin with stable dose for at least 4 weeks~* Lipid lowering therapy has been stable prior to enrollment~* Fasting triglycerides must be \< 400 mg/dL.~* Subject not at LDL-C goal~Exclusion Criteria:~* New York Heart Association (NYHA) III or IV heart failure or known left ventricular ejection fraction \< 30%~* Uncontrolled cardiac arrhythmia~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization~* Type 1 diabetes or newly diagnosed type 2 diabetes (HbA1c \> 8.5%)~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
- Evolocumab + Ezetimibe (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
- Evolocumab 280 mg (Type: EXPERIMENTAL): Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 350 mg (Type: EXPERIMENTAL): Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 420 mg (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A male or female age between 18 and 64 years at the time of the first vaccination.~* non-childbearing female~Exclusion Criteria:~* Use of non-registered products~* Pregnancy~* Hypersensitivity to a previous dose of influenza vaccine~* Acute disease at the time of enrolment/vaccination.~* History of allergy or reactions likely to be exacerbated by any component of the vaccine~* Administration of any other influenza vaccine for the season 2006-2007~* Chronic disorders of the pulmonary or cardiovascular system, including asthma.~* Administration of immune-modifying drugs~* Administration of immunoglobulins and/or any blood products~* History of requiring regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, asthma or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have advanced-stage cancer and anxiety.~* Be between the ages of 18 - 70.~Note: The location for the two treatment sessions is Los Angeles, California. Treatment sessions are scheduled three to six weeks apart, and they include one overnight hospital stay both times.~Exclusion Criteria:~* Not have cancer that affects the central nervous system or brain function.~* Have no history of major psychiatric disorder.~* Have no kidney disease, abnormal liver functions, epilepsy, or cardiovascular disease, including untreated hypertension.~* Not be taking insulin, oral hypoglycemic, anti-seizure, or cardiovascular medications (except anti-hypertensive drugs).~* May take PRN benzodiazepines up to 3 days before the session.~* No Prozac for the previous 5 weeks.~* No medications the day of and the day after treatment sessions, except may take ongoing adjuvant chemotherapy as prescribed, prescribed or over-the-counter non-narcotic pain medication at any time, and narcotic pain medications up to eight hours before administration of psilocybin and six hours after administration.~* No alcohol consumption the day before, the day of, and the day after a session.~* Female subjects of childbearing potential must have a negative pregnancy test and agree to use an effective form of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): Single, 6-hour treatment with 0.2 mg/kg active psilocybin capsule.
- Active Niacin Placebo (Type: ACTIVE_COMPARATOR): Each subject functioned as their own control, receiving niacin placebo capsule in a single 6-hour session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Subjects are enrolled in this study if they:~* Met entrance criteria and were enrolled and imaged in trial 18F-AV-45-A07 (NCT00857415)~* Gave informed consent for the 18F-AV-45-A07 (NCT00857415) study procedures and brain donation consistent with the legal requirements of the State in which they are enrolled and the State in which they die~* Consent to participate in the 18F-AV-45-A16 (NCT01447719) extension protocol, if required by the IRB~* Reconfirm their consent to a research brain autopsy, if required by the IRB.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB-SC) Using a Novel Fork Needle

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients who are 18 years old or older and are referred for the evaluation of pancreatic mass lesion.~* International Normalized Ratio (INR) less than 1.5 and platelet count of more than 50,000.~* Medically stable to undergo sedation for EUS.~* Signed informed consent~Exclusion Criteria:~* Medical condition that preclude the patient from having a therapeutic procedure regardless of the EUS finding~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- FNB first, then FNA (Type: ACTIVE_COMPARATOR): In an endoscopic ultrasound-guided procedure, Shark Core Fine Needle Biopsy (FNB) will be performed first, followed by Fine Needle Aspiration (FNA).
- FNA first, then FNB (Type: ACTIVE_COMPARATOR): In an endoscopic ultrasound-guided procedure, Fine Needle Aspiration (FNA) will be performed first, followed by Shark Core Fine Needle Biopsy (FNB).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Patient indicated for biliary metal stent placement for the treatment of jaundice and/or cholestasis~* Willing and able to comply with the study procedures and provide written informed consent to participate in the study~* Suspicion of pancreatic adenocarcinoma~* Likely indicated for neoadjuvant treatment~* Distal biliary obstruction consistent with pancreatic cancer~* Location of distal biliary obstruction such that it would allow the proximal end of a stent to be positioned at least 2 cm from the hilum~* Endoscopic and surgical treatment to be provided at the same institution~Exclusion Criteria:~* Benign biliary strictures~* Malignancy secondary to Intraductal Papillary Mucinous Neoplasm~* Surgically altered anatomy where ERCP is not possible~* Previous biliary drainage using a SEMS or multiple plastic stents~* Contraindications for endoscopic techniques~* Patients who are currently enrolled in another investigational trial that would directly interfere with the current study~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WallFlex Biliary RX Fully Covered Stent System (Type: ACTIVE_COMPARATOR): Patients in this group will receive a fully covered study SEMS (self-expanding metal stent)~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System
- WallFlex Biliary RX Uncovered Stent System (Type: ACTIVE_COMPARATOR): Patients in this group will receive an uncovered study SEMS (self-expanding metal stent).~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone and Mid-Trimester Termination of Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 16 years of age or over~* able to give informed consent in English or Spanish~* Requesting termination of pregnancy~Exclusion Criteria:~* Under 16 years of age~* rupture membranes or intrauterine death

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patients aged from18- 60 years.~2. Chronic HCV infection with Plasma HCV RNA greater than 15,000 IU/mL~3. Treatment naïve.~4. compensated liver cirrhosis.~5. Absence of coinfection with HBV or HIV.~Exclusion Criteria:~1. Patients with hepatitis B virus or HIV.~2. prior antiviral therapy.~3. Haemoglobin level less than 10mg/dl.~4. Decompensated liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ombitasvir (25 mg ), Paritaprevir (150 mg ) once daily (Type: OTHER): Ombitasvir (25 mg once daily), Paritaprevir (150 mg once daily), Ritonavir (100 mg once daily)Ribavirin (RBV): weight-based and divided bid (1000 mg/day if \< 75kg or 1200 mg/day if ≥ 75kg) given to 50 chronic HCV infected patients with renal impairment for 12 week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* affiliated or beneficiary of a social security category~* having signed the inform consent form~* having signed the genetic consent form~* BMI between 18.5 and 25~* normal clinical exam~* normal biological exam~Exclusion Criteria:~* contra-indication to rivaroxaban~* contra-indication to activated charcoal~* previous history of psychiatric disease, or antidepressant treatment, or convulsion, or hemorrhagic disease smoker~* Organic lesion likely to bleed~* severe liver disease~* severe kidney failure~* previous surgery within one month

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Arm A (Type: EXPERIMENTAL): * Period  rivaroxaban alone~* Washout period (at least 6 days)~* Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration~* Washout period (at least 6 days)~* Period   rivaroxaban and activated charcoal 5 hours after rivaroxaban administration
- Arm B (Type: EXPERIMENTAL): . Period  rivaroxaban and activated charcoal 5 hours after rivaroxaban administration~* Washout period (at least 6 days)~* Period  rivaroxaban alone~* Washout period (at least 6 days)~* Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration
- Arm C (Type: EXPERIMENTAL): . Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration~* Washout period (at least 6 days)~* Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration~* Washout period (at least 6 days)~* Period  rivaroxaban alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic castration-resistant prostate cancer (CRPC)~* Previous anti-androgen therapy and progression after withdrawal~* ECOG performance status of either 0 or 1~* Medical or surgical castration with testosterone less than 50 ng/dL~* Life expectancy of at least 6 months~Exclusion Criteria:~* Prior cytotoxic chemotherapy or biologic therapy for CRPC~* Prior ketoconazole for prostate cancer~* Known brain metastasis or visceral organ metastasis~* Use of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo + prednisone (Type: PLACEBO_COMPARATOR): Placebo plus prednisone
- Abiraterone + prednisone (Type: EXPERIMENTAL): Abiraterone acetate plus prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female between 6 and 12 years of age, inclusive, at the time of Screening.~2. Diagnosed as meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for ADHD.~3. A clinician-administered Clinical Global Impression of Severity (CGI-S) score of 3 or greater.~4. An ADHD Rating Scale (ADHD-RS) score at Screening and Baseline greater than or equal to the 90th percentile normative values for gender and age in at least one of the following categories: hyperactive-impulsive subscale, inattentive subscale, or total score.~Exclusion Criteria:~1. Secondary or co-morbid diagnoses other than ADHD, with the exception of simple phobias, oppositional defiant disorder, elimination disorders, motor skills disorders, communication disorders, learning disorders, adjustment disorders, and sleep disorders if, in the opinion of the investigator, the associated symptoms do not confound assessment of safety or efficacy.~2. Clinically significant cognitive impairment as assessed in the clinical judgment of the Investigator.~3. History of any of the following medical disorders: seizure disorder (excluding a history of febrile seizures), structural cardiac disorders, serious cardiac conditions, hypertension, untreated thyroid disease, glaucoma, Tourette's disorder, or chronic tics.~4. Clinically significant abnormal ECG finding or abnormal cardiac finding on physical exam (including presence of a pathologic murmur) at Screening.~5. Use of any psychotropic medication (sedative hypnotics prescribed as a sleep aid at a stable dose for at least 30 days prior to Baseline, at bedtime only, are allowed during the study).~6. A history of hypersensitivity or intolerance to any formulation of amphetamine or lisdexamfetamine.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- AR11 (amphetamine sulfate) (1 week) - double blind (Type: EXPERIMENTAL): AR11, administered orally, BID, for one week (crossover to placebo administration week 2)
- Placebo (1 week) - double blind (Type: PLACEBO_COMPARATOR): Placebo, administered orally, BID, for one week (crossover to AR11 administration week 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete